Recent research suggests that targeting M2 macrophages could be a promising therapeutic approach for treating psoriasis, especially through advanced biologic treatments such as anti‐IL‐17 and anti‐IL‐23 therapies. The gene discussed is IL17A; the disease is psoriasis.